REG - ReNeuron Group plc - Posting of Annual Report & Notice of AGM <Origin Href="QuoteRef">RQE.L</Origin>

ReNeuronAnnouncement

06/09/2014 16:48

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140717:nRSQ5920Ma


RNS Number : 5920M
ReNeuron Group plc
17 July 2014 
 
 17 July 2014  AIM: RENE  
 
 
AIM: RENE 
 
ReNeuron Group plc 
 
("ReNeuron" or the "Company") 
 
Posting of Annual Report & Accounts and Notice of AGM 
 
Guildford, UK, 17 July 2014: ReNeuron Group plc (AIM: RENE) announces that its
Annual Report and Accounts for the year ended 31 March 2014 and the Notice of
the 2014 Annual General Meeting ("AGM") have been sent to shareholders and are
also available on the Company's website at www.reneuron.com. 
 
ReNeuron's AGM will be held at 10:00am on Tuesday 2 September 2014 at the
offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH. 
 
Enquiries: 
 
ReNeuron Group plc 
 
Richard Moulson, Interim CFO                                                  
  +44 (0) 1483 302560 
 
Buchanan 
 
Mark Court, Fiona Henson, Sophie Cowles                            +44 (0) 20
7466 5000 
 
Cenkos Securities 
 
Chris Golden (NOMAD & Broker)                                               
+44 (0) 20 7397 8900 
 
About ReNeuron 
 
ReNeuron is a leading, clinical-stage stem cell business.  Its primary
objective is the development of novel stem cell therapies targeting areas of
significant unmet or poorly met medical need. 
 
ReNeuron has used its unique stem cell technologies to develop cell-based
therapies for significant disease conditions where the cells can be readily
administered "off-the-shelf" to any eligible patient without the need for
additional immunosuppressive drug treatments.  ReNeuron's lead candidate is
its ReN001 stem cell therapy for the treatment of patients left disabled by
the effects of a stroke. This therapy is currently in clinical development. 
The Company is also developing stem cell therapies for other conditions such
as critical limb ischaemia, a serious and common side-effect of diabetes, and
blindness-causing diseases of the retina such as retinitis pigmentosa. 
 
ReNeuron has also developed a range of stem cell lines for non-therapeutic
applications - its ReNcell products for use in academic and commercial
research.  The Company's ReNcellCX and ReNcellVM neural cell lines are
marketed worldwide under license by USA-based Merck Millipore. 
 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
 Further information on ReNeuron and its products can be found at
www.reneuron.com. 
 
This information is provided by RNS
The company news service from the London Stock Exchange